Advertisement
Screener

Oncotelic Therapeutics, Inc. (OTLC) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period

Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period

Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 500.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13

  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 0.00 shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 500.00K shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 0.00 shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 375.00K shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 1.51M shares, a 64016.15% increase from fiscal 2022.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 2.36K shares, a 63.59% increase from fiscal 2021.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 1.44K shares, a 99.93% decline from fiscal 2020.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month
2026-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
500.00K shares
10-Q · filed 2026-08-13
500.00K shares
derived: sum of 3 quarters · filed 2026-08-13
500.00K shares
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31500.00K shares
10-Q · filed 2026-05-14
500.00K shares
derived: sum of 2 quarters · filed 2026-05-14
500.00K shares
derived: sum of 3 quarters · filed 2026-05-14
2025-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
0.00 shares
derived: sum of 2 quarters · filed 2026-04-15
375.00K shares
10-K · filed 2026-04-15
2025-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17
375.00K shares
10-Q · filed 2025-11-17
2025-06-30375.00K shares
10-Q · filed 2025-08-13
2023-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
0.00 shares
derived: sum of 2 quarters · filed 2025-04-15
1.51M shares
10-K · filed 2025-04-15
2023-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19
1.51M shares
10-Q · filed 2024-11-19
2023-06-301.51M shares
10-Q · filed 2024-08-14
2022-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-12
0.00 shares
derived: sum of 2 quarters · filed 2024-04-12
0.00 shares
derived: sum of 3 quarters · filed 2024-04-12
2.36K shares
10-K · filed 2024-04-12
2022-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
0.00 shares
derived: sum of 2 quarters · filed 2023-11-14
2.36K shares
10-Q · filed 2023-11-14
2022-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18
2.36K shares
10-Q · filed 2023-08-18
2022-03-312.36K shares
10-Q · filed 2023-05-22
2021-12-311.44K shares
10-K/A · filed 2023-04-20
2020-12-312.19M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15
2.19M shares
derived: sum of 2 quarters · filed 2022-04-15
2.19M shares
derived: sum of 3 quarters · filed 2022-04-15
2.20M shares
10-K · filed 2022-04-15
2020-09-305.28K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16
5.28K shares
derived: sum of 2 quarters · filed 2020-11-16
15.04K shares
10-Q · filed 2020-11-16
15.04K shares
derived: sum of 4 quarters · filed 2021-04-15
2020-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
9.76K shares
10-Q · filed 2020-08-14
9.76K shares
derived: sum of 3 quarters · filed 2021-04-15
342.64K shares
derived: sum of 4 quarters · filed 2021-04-15
2020-03-319.76K shares
10-Q · filed 2020-06-29
9.76K shares
derived: sum of 2 quarters · filed 2021-04-15
342.64K shares
derived: sum of 3 quarters · filed 2021-04-15
2019-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-15
332.88K shares
derived: sum of 2 quarters · filed 2021-04-15
640.57K shares
10-K · filed 2021-04-15
2019-09-30332.88K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-19
640.57K shares
10-Q · filed 2019-11-19
2019-06-30307.69K shares
10-Q · filed 2019-08-19
2015-03-318.00K shares
10-Q · filed 2015-05-07
8.00K shares
derived: sum of 2 quarters · filed 2015-05-07
34.00K shares
derived: sum of 3 quarters · filed 2015-05-07
2014-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
26.00K shares
derived: sum of 2 quarters · filed 2015-03-30
41.00K shares
10-K · filed 2015-03-30
2014-09-3026.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13
41.00K shares
10-Q · filed 2014-11-13
2014-06-3015.00K shares
10-Q · filed 2014-08-08
2013-12-3113.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
16.00K shares
derived: sum of 2 quarters · filed 2015-03-30
29.00K shares
derived: sum of 3 quarters · filed 2015-03-30
58.00K shares
10-K · filed 2015-03-30
2013-09-303.00K shares
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-13
16.00K shares
derived: sum of 2 quarters · filed 2013-11-13
45.00K shares
10-Q · filed 2013-11-13
-582.00K shares
derived: sum of 4 quarters · filed 2015-03-30
2013-06-3013.00K shares
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2013-10-18
42.00K shares
10-Q/A · filed 2013-10-18
-585.00K shares
derived: sum of 3 quarters · filed 2015-03-30
-442.00K shares
derived: sum of 4 quarters · filed 2015-03-30
2013-03-3129.00K shares
10-Q · filed 2013-05-09
-598.00K shares
derived: sum of 2 quarters · filed 2015-03-30
-455.00K shares
derived: sum of 3 quarters · filed 2015-03-30
2012-12-31-627.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
-484.00K shares
derived: sum of 2 quarters · filed 2015-03-30
64.00K shares
10-K · filed 2015-03-30
2012-09-30143.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
691.00K shares
10-Q · filed 2012-11-09
2012-06-30548.00K shares
10-Q · filed 2012-08-13
2011-12-3114.00K shares
10-K · filed 2014-03-20
2010-12-312.00K shares
10-K · filed 2013-03-15